Genomic Risk in Retroperitoneal Sarcoma

Status Recruiting

Clinical Trial Summary

The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06436846
Study type	Observational
Source	Fox Chase Cancer Center
Contact	Anthony Villano, MD
Phone	215-728-3686
Email	anthony.villano@fccc.edu
Status	Recruiting
Phase
Start date	March 7, 2022
Completion date	August 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02910895` - A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)	N/A
Recruiting	`NCT05621668` - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma	Phase 1
Active, not recruiting	`NCT04032964` - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS	Phase 1
Active, not recruiting	`NCT04577014` - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Completed	`NCT01650077` - Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Completed	`NCT02204111` - Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Withdrawn	`NCT01663090` - Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas	N/A
Completed	`NCT01259375` - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma	Phase 2
Completed	`NCT01440088` - A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	Phase 3
Completed	`NCT01106872` - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	Phase 1
Recruiting	`NCT00753727` - Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma	Phase 1/Phase 2
Terminated	`NCT00755261` - Phase II Study of Doxorubicin and Avastin® in Sarcoma.	Phase 2
Completed	`NCT00580320` - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Phase 1
Completed	`NCT00611078` - Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study	N/A
Completed	`NCT03452644` - US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
Recruiting	`NCT05539677` - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Terminated	`NCT03520959` - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)	Phase 3